Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
Luckily for you, we at StockStory have no conflicts of interest - our sole job is to help you find genuinely promising companies. Keeping that in mind, here is one stock where Wall Street’s positive outlook is supported by strong fundamentals and two where consensus estimates seem disconnected from reality.
Two Stocks to Sell:
Inspired (INSE)
Consensus Price Target: $13.33 (41.8% implied return)
Specializing in digital casino gaming, Inspired (NASDAQ: INSE) is a provider of gaming hardware, virtual sports platforms, and server-based gaming systems.
Why Are We Wary of INSE?
- Lackluster 1.1% annual revenue growth over the last two years indicates the company is losing ground to competitors
- Estimated sales decline of 1.8% for the next 12 months implies a challenging demand environment
- Poor free cash flow margin of 1.8% for the last two years limits its freedom to invest in growth initiatives, execute share buybacks, or pay dividends
At $9.40 per share, Inspired trades at 2.5x forward EV-to-EBITDA. Check out our free in-depth research report to learn more about why INSE doesn’t pass our bar.
Biogen (BIIB)
Consensus Price Target: $171.96 (22.8% implied return)
Founded in 1978 and pioneering treatments for some of medicine's most complex challenges, Biogen (NASDAQ: BIIB) develops and markets therapies for neurological conditions, including multiple sclerosis, Alzheimer's disease, spinal muscular atrophy, and rare diseases.
Why Does BIIB Worry Us?
- Annual sales declines of 7.2% for the past five years show its products and services struggled to connect with the market during this cycle
- Estimated sales decline of 7% for the next 12 months implies an even more challenging demand environment
- Performance over the past five years shows each sale was less profitable as its earnings per share dropped by 15.2% annually, worse than its revenue
Biogen’s stock price of $140 implies a valuation ratio of 9.3x forward P/E. Dive into our free research report to see why there are better opportunities than BIIB.
One Stock to Watch:
Cardinal Health (CAH)
Consensus Price Target: $180.46 (20.8% implied return)
Operating as a critical link in the healthcare supply chain since 1979, Cardinal Health (NYSE: CAH) distributes pharmaceuticals and manufactures medical products for hospitals, pharmacies, and healthcare providers across the global healthcare supply chain.
Why Are We Fans of CAH?
- Unparalleled scale of $222.6 billion in revenue gives it negotiating leverage and staying power in an industry with high barriers to entry
- Projected revenue growth of 11.9% for the next 12 months indicates demand will rise above its two-year trend
- Earnings per share grew by 8.6% annually over the last five years, above the peer group average
Cardinal Health is trading at $149.45 per share, or 16.2x forward P/E. Is now the right time to buy? See for yourself in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.
The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
